Halozyme Therapeutics (NASDAQ:HALO) Director Sells $124,653.75 in Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Bernadette Connaughton sold 1,625 shares of the business’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $76.71, for a total value of $124,653.75. Following the transaction, the director owned 42,044 shares in the company, valued at approximately $3,225,195.24. This trade represents a 3.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bernadette Connaughton also recently made the following trade(s):

• On Monday, June 1st, Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $66.21, for a total value of $107,591.25.
• On Friday, May 1st, Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $63.48, for a total transaction of $103,155.00.

Halozyme Therapeutics Stock Performance

Halozyme Therapeutics stock traded up $2.44 during mid-day trading on Thursday, reaching $79.45. 1,558,182 shares of the company traded hands, compared to its average volume of 1,799,850. The firm’s fifty day moving average is $68.96 and its two-hundred day moving average is $69.23. The company has a market capitalization of $9.42 billion, a price-to-earnings ratio of 28.58, a price-to-earnings-growth ratio of 0.32 and a beta of 0.84. Halozyme Therapeutics, Inc. has a fifty-two week low of $53.33 and a fifty-two week high of $82.22. The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 2.33.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.06. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The firm had revenue of $376.71 million for the quarter, compared to analyst estimates of $358.60 million. During the same period in the previous year, the company earned $1.11 earnings per share. The business’s quarterly revenue was up 42.2% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, equities research analysts expect that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Halozyme Therapeutics

Institutional investors have recently modified their holdings of the business. DLD Asset Management LP boosted its position in Halozyme Therapeutics by 20.0% during the third quarter. DLD Asset Management LP now owns 30,000,000 shares of the biopharmaceutical company’s stock worth $2,200,200,000 after purchasing an additional 5,000,000 shares in the last quarter. Norges Bank acquired a new position in shares of Halozyme Therapeutics during the 4th quarter worth approximately $128,201,000. William Blair Investment Management LLC acquired a new position in shares of Halozyme Therapeutics during the 4th quarter worth approximately $124,031,000. Voloridge Investment Management LLC purchased a new position in shares of Halozyme Therapeutics during the 3rd quarter valued at approximately $77,587,000. Finally, Qube Research & Technologies Ltd acquired a new stake in Halozyme Therapeutics in the 2nd quarter valued at $51,295,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

HALO has been the subject of a number of research reports. Weiss Ratings upgraded shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, May 12th. Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. UBS Group reissued a “buy” rating and issued a $90.00 price objective on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Wall Street Zen raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Finally, Morgan Stanley decreased their price target on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. Eight analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $81.60.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.